Final CFSAN review at Science Board
This article was originally published in The Tan Sheet
Executive Summary
FDA's Science Board on Aug. 16 will discuss a subcommittee's final report on the Center for Food Safety and Applied Nutrition's research, a June 29 Federal Register 1notice says. The subcommittee's interim report, presented in February, said CFSAN's laboratory infrastructure has minimal administrative support and little flexibility (2"The Tan Sheet" March 1, 2010, In Brief). The subcommittee began the review in August 2009 and will review intramural research in each FDA center. The Center for Drug Evaluation and Research is next, and the board will discuss an interim report from the CDER subcommittee at the meeting in Bethesda, Md
You may also be interested in...
CFSAN runs lean operation
The laboratory infrastructure within FDA's Center for Food Safety and Applied Nutrition has minimal administrative support and little flexibility, according to an interim report on research review presented by an FDA Science Board subcommittee. "There's not as much of a support system within CFSAN," said subcommittee member Rhona Applebaum during the Feb. 22 Science Board meeting in Bethesda, Md. "Oftentimes what we saw and what we heard is, we're asking our chefs to be also the chief cooks and bottle washers." Applebaum, VP and chief scientific and regulatory officer for Coca-Cola, added that the food center is stretched thin performing crucial tasks to protect public health. The subcommittee will continue reviewing CFSAN activities and present its final report at a May 17 Science Board meeting. The Obama administration proposed a 32.9 percent increase to $1.04 billion in FDA food program funding for fiscal 2011 (1"The Tan Sheet" Feb. 8, 2010)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.